CTI BioPharma

CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.
Type
Public
HQ
Seattle, US
Founded
1992
Size (employees)
100 (est)-32%
CTI BioPharma was founded in 1992 and is headquartered in Seattle, US

CTI BioPharma Office Locations

CTI BioPharma has an office in Seattle
Seattle, US (HQ)
600 3101 Western Ave

CTI BioPharma Metrics

CTI BioPharma Financial Metrics

Revenue (2016)

$57.4 m

Revenue growth (2015-16), %

256%

Net income (2016)

($53 m)

Market capitalization (21-Mar-2017)

$120.3 m

Closing share price (21-Mar-2017)

$4.2

Cash (31-Dec-2016)

$44 m
CTI BioPharma's current market capitalization is $120.3 m.
CTI BioPharma's revenue was reported to be $57.4 m in FY, 2016 which is a 256.2% increase from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$319 k$34.7 m$60.1 m$16.1 m$57.4 m

Revenue growth, %

73%(73%)256%

Cost of goods sold

$137 k$895 k$1.9 m

Gross profit

$34.5 m$59.2 m$14.2 m

Gross profit Margin, %

100%99%88%

Operating expense total

$76.1 m$146.3 m$130.8 m

EBIT

($41.5 m)($86.2 m)($116.7 m)($49.2 m)

EBIT margin, %

(120%)(144%)(724%)(86%)

Interest expense

$2.2 m$870 k$56 k$1 m$1.9 m$2.1 m$2.6 m

Net Income

($43.6 m)($94.2 m)($120.8 m)($53 m)
Y, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

$37.8 m$22.6 m$47.1 m$50.4 m$71.6 m$70.9 m$128.2 m$44 m

Accounts Receivable

$235 k$2 m$282 k$378 k

Inventories

$3.6 m$3.4 m$3.7 m$2.1 m

Current Assets

$80.5 m$80.5 m$135 m$55.8 m

PP&E

$5.5 m$4.6 m$3.7 m$3 m

Total Assets

$93.7 m$92.3 m$144.3 m$63.8 m

Accounts Payable

$5.1 m$6.4 m$10.6 m$7.2 m

Current Liabilities

$20.1 m$36.3 m$72.4 m$40.6 m

Retained Earnings

($1.9 b)($2 b)($2.1 b)($2.2 b)

Total Equity

$42.8 m$38.5 m$47.4 m$7.8 m

Financial Leverage

2.2 x2.4 x3 x8.2 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($43.6 m)($94.2 m)($120.8 m)($53 m)

Depreciation and Amortization

$1.6 m$1.1 m$990 k$831 k

Accounts Receivable

($227 k)($2 m)$1.6 m($156 k)

Inventories

$4.5 m$46 k($402 k)$1.6 m

Accounts Payable

($5.8 m)$1.5 m$4.4 m($3 m)

Cash From Operating Activities

($35.8 m)($39.6 m)($95.2 m)($76.7 m)

Purchases of PP&E

($1.7 m)($333 k)($78 k)($137 k)

Cash From Investing Activities

($1.5 m)($541 k)($78 k)($137 k)

Long-term Borrowings

($1.5 m)

Interest Paid

$933 k$1.9 m$2.1 m$4.4 m

Income Taxes Paid

CTI BioPharma Market Value History

CTI BioPharma Online Presence

CTI BioPharma Company Life

You may also be interested in